Lifecore Biomedical Inc. Asset Resilience Ratio
Lifecore Biomedical Inc. asset resilience ratio. Lifecore Biomedical Inc. (LFCR) has an Asset Resilience Ratio of 0.03% as of February 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read LFCR current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lifecore Biomedical Inc. (2005–2013)
Asset resilience ratio of Lifecore Biomedical Inc. from 2005 to 2013. This chart shows how Lifecore Biomedical Inc.'s Asset Resilience Ratio has changed over time. See Lifecore Biomedical Inc. free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Lifecore Biomedical Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Lifecore Biomedical Inc. balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $86.00K | 0.03% |
| Total Liquid Assets | $86.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Lifecore Biomedical Inc. maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lifecore Biomedical Inc. Industry Peers by Asset Resilience Ratio
Compare Lifecore Biomedical Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Lifecore Biomedical Inc. Asset Resilience Ratio by Year (2005–2013)
Lifecore Biomedical Inc. asset resilience ratio by year from 2005 to 2013. The table below shows the annual Asset Resilience Ratio data for Lifecore Biomedical Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2013-05-31 | 0.53% | $1.54 Million | $290.94 Million | -13.10pp |
| 2011-05-31 | 13.63% | $28.12 Million | $206.31 Million | +3.43pp |
| 2010-05-31 | 10.20% | $20.42 Million | $200.20 Million | -4.52pp |
| 2009-05-31 | 14.72% | $22.50 Million | $152.87 Million | +4.99pp |
| 2008-05-31 | 9.72% | $14.64 Million | $150.59 Million | +7.76pp |
| 2005-05-31 | 1.97% | $1.97 Million | $100.08 Million | -- |
About Lifecore Biomedical Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device … Read more